Open AccessAldosterone antagonists in cardiology practice
Author(s) -
А.И. Данилов,
Данилов Андрей Игоревич,
С. Н. Козлов,
Козлов Сергей Николаевич,
А. В. Евсеев,
Евсеев Андрей Викторович
Publication year - 2019
Publication title -
obzory po kliničeskoj farmakologii i lekarstvennoj terapii
Language(s) - English
Resource type - Journals
eISSN - 2542-1875
pISSN - 1683-4100
DOI - 10.17816/rcf17273-77
Subject(s) - eplerenone , spironolactone , hyperkalemia , aldosterone , medicine , drug reaction , adverse effect , drug , adverse drug reaction , cardiology , pharmacology , intensive care medicine
In review presents the patological effects of aldosterone, clinical pharmacology of aldosterone antagonists and their role in countering the development of cardiovascular diseases are highlighted. The results of clinical studies have demonstrated high clinical efficacy and safety of spironolactone and eplerenone in a wide range of cardiovascular risk. However, the potential adverse drug reactions associated with these drugs limit their use in some categories of patients. However, adequate monitoring of these reactions, including hyperkalemia and acute kidney injury, can be avoided. In situations where there are indications for the use of spironolactone or eplerenone, the latter is the drug of choice due to the lower risk of gender adverse reactions. The frequency of other adverse drug reactions, in particular hyperkalemia, spironolactone and eplerenone are comparable.